The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Binimetinib

Geo Regions

Binimetinib
Share to an HCP

Overview + Rationale

  • The mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 are upstream regulators of the mitogen-activated protein kinase (MAPK) cascade 
  • This cascade regulates diverse cellular functions, including cell proliferation, survival, differentiation, and migration, and is deregulated in numerous cancer types 
  • BRAF inhibition in BRAF-mutant melanoma is limited by intrinsic and acquired resistance. Reactivation of the MAPK pathway drives BRAF-inhibitor resistance and is a contributor to treatment failure in BRAF-mutant melanoma 
  • Binimetinib is an orally available inhibitor of mitogen-activated protein kinase 1 and 2 (MEK1/2) with potential antineoplastic activity 
  • This may eventually lead to an inhibition of tumor cell proliferation and an inhibition in production of various inflammatory cytokines, including interleukin-1, -6, and tumor necrosis factor

Mechanism of Action

  • Binimetinib is a reversible inhibitor of MEK1 and MEK2 activity. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway 
  • In vitro, binimetinib inhibited extracellular signal related kinase (ERK) phosphorylation in cell-free assays as well as viability and MEK-dependent phosphorylation of BRAF-mutant (eg, V600e) human melanoma cell lines 
  • Binimetinib also inhibited in vivo ERK phosphorylation and tumor growth in BRAF-mutant murine xenograft models

Stage of Development

Binimetinib is being investigated in combination with other agent(s) in the tumor types shown here. Safety and efficacy of binimetinib in combination for the uses listed below has not been established.

small icon representing melanoma
BRAF V600E/K-mutant+ Metastatic or Unresectable Locally Advanced Melanoma
Phase 3 (1L) Combination*

*Closed to enrollment

REFERENCES:  Array BioPharma Inc. MEKTOVI® (binimetinib) US Prescribing Information. Knight T, Irving JA. Ras/Raf/MEK/ERK pathway activation in childhood acute lymphoblastic leukemia and its therapeutic targeting. Front Oncol. 2014;4:160. Tran KA et al. MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy. Drug Des Devel Ther. 2015;10:43-52. National Cancer Institute. NCI Drug Dictionary: binimetinib. Accessed May 16, 2023. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/binimetinib; ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT04657991; Accessed July 23, 2024.